Skip to main content

JAK/TYK2

      THE ASSOCIATION BETWEEN DEPRESSION AND BIOLOGIC PRESCRIBING IN AXIAL SPONDYLOARTHRITIS (axSpA): LESSONS FROM AN IRISH ax
      6 months ago
      THE ASSOCIATION BETWEEN DEPRESSION AND BIOLOGIC PRESCRIBING IN AXIAL SPONDYLOARTHRITIS (axSpA): LESSONS FROM AN IRISH axSpA COHORT more likely to have peripheral arthritis enthesitis psoriasis - shoukd we be formally assessing eg Beck’s DI @RheumNow #EULAR2024
      #EULAR2024 LBA0001 New Steroid-sparring therapy for #GCA. Phase 3 RCT showed Upadacitinib 15mg met primary endpoint (sus
      #EULAR2024 LBA0001 New Steroid-sparring therapy for #GCA. Phase 3 RCT showed Upadacitinib 15mg met primary endpoint (sustained clin remission frm Wks 12-52 & adherence to 26Wk GC taper) vs PBO [46% vs 29%] & multiple secondary endpoints. No new safety signals @RheumNow https://t.co/edfSZkMuy2
      LBA0001 UPA in GCA- Phase 2 RCT

      15mg UPA with 26w steroid taper showed
      ⬆️ efficacy
      ⬇️ steroid use
      vs placebo wi
      6 months ago
      LBA0001 UPA in GCA- Phase 2 RCT 15mg UPA with 26w steroid taper showed ⬆️ efficacy ⬇️ steroid use vs placebo with 52w steroid taper Potential new target on the horizon for #GCA?? @RheumNow #EULAR2024
      POS0231 Safety of JAKi vs TNFi or IL-17 inhibitors in #PsA & #SpA

      Results from a large population-based study show
      6 months ago
      POS0231 Safety of JAKi vs TNFi or IL-17 inhibitors in #PsA & #SpA Results from a large population-based study show reassuring data, with no increased risk of #CVD, #VTE or certain cancers compared to TNFi or IL-17i @SteZhao @RheumNow #EULAR2024
      1200 PsA pts 6 countries IL17is as effective as TNFi and JAK despite more failed bDMARDs and monotherapy & faster on
      6 months ago
      1200 PsA pts 6 countries IL17is as effective as TNFi and JAK despite more failed bDMARDs and monotherapy & faster onset action than IL23s ⁦@RheumNow⁩ #EULAR2024 https://t.co/SM5CA7KUvd
      Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

      Dr. Eric Ruderman shares his perspectives on the follow
      6 months ago
      Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at #EULAR2024 in Vienna, Austria: OP0195 LBA0005 POS0803 OP0138 https://t.co/MnefRxYqMh https://t.co/Mwq4s7eTKY
      EFFICACY AND SAFETY OUTCOMES OF TAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-
      6 months ago
      EFFICACY AND SAFETY OUTCOMES OF TAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS - smells tastes & looks like a Tyk2 - acne signal? @rheumnow #EULAR2024
      The development of JAK inhibitors represents an advance for the treatment of inflammatory rheumatic diseases. However, the enthusiasm in using this target has waned since the publication of the ORAL…
      #wasup in #GCA?

      #upadacitinib +RCT in #temporal #arteritis LBA0001

      Residual #inflammation in 1/3 of pts at 6 mo #Rx w
      6 months ago
      #wasup in #GCA? #upadacitinib +RCT in #temporal #arteritis LBA0001 Residual #inflammation in 1/3 of pts at 6 mo #Rx w #TCZ on repeat TA Bx OP0621 #PMR cases #Leflunomide beats #MTX for #pred sparing ⬇️relapses But MTX dose was low POS0280 #EULAR2024 @RheumNow @eular_org
      ×